Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...
Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.
Ozempic — or any of the GLP-1 class of diet drugs that includes Wegovy and Mounjaro — hasn’t just changed our nation’s ...
There has been a lot of conversation lately about if new weight loss drugs like Wegovy and Mounjaro should be covered by ...
The Biden administration proposed a rule for Medicare and Medicaid to cover the costs of weight-loss drugs for millions of Americans with obesity.
In December 2022, the Food and Drug Administration approved Wegovy for weight-management in adolescents ages 12 and older ...
The good news is that HHS recognizes that vitally important anti-obesity medicines like Wegovy and Zepbound should be made available to all Americans, regardless of income. The bad news is that unless ...
About 7.4 million Americans with obesity could have insurance coverage for drugs like Wegovy if the Trump administration ...
The new rule would expand access to the drugs for 3.4 million Americans who use Medicare and another 4 million people ...
It would give millions of people access to weekly injectables that have helped people shed pounds so quickly that some people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback